Beginning of prescription competition between Tresiba and Toujeo
The active competition among next-generation insulin has begun.
According to the industry concerned on the 28th, after Novo Nordisk registered the health insurance benefit of ‘Tresiba(insulin degludec),’ a basal insulin, ‘Toujeo, ’a Sanofi-Aventis’s gene recombination product of ‘Lantus(insulin ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
